Amoxicillin - Generic Drug Details

What are the generic sources for amoxicillin and what is the scope of freedom to operate?

Amoxicillin is the generic ingredient in twenty-five branded drugs marketed by Aurobindo, Chartwell, Hikma Pharms, Labs Atral, Micro Labs, Mylan, Sandoz, Strides Pharma Intl, Sun Pharm Inds Ltd, Teva, Glaxosmithkline, Us Antibiotics, Apothecon, Parke Davis, Wyeth Ayerst, Aurobindo Pharma Ltd, Chartwell Rx, Hikma, Ph Health, Pragma, Ranbaxy Labs Ltd, Ani Pharms, Rising, Takeda Pharms Usa, Cumberland, Phathom, Aurobindo Pharma, Cipla, Deva Holding As, Micro Labs Ltd India, Sandoz Inc, Apotex Inc, Teva Pharms Usa, and Talicia Holdings, and is included in one hundred and twenty-six NDAs. There are twelve patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Amoxicillin has eleven patent family members in six countries.

There are forty-six drug master file entries for amoxicillin. Thirty-nine suppliers are listed for this compound.

Summary for amoxicillin

International Patents:	11
US Patents:	12
Tradenames:	25
Applicants:	34
NDAs:	126
Drug Master File Entries:	46
Finished Product Suppliers / Packagers:	39
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	680
Patent Applications:	7,076
Drug Prices:	Drug price trends for amoxicillin
Drug Sales Revenues:	Drug sales revenues for amoxicillin
What excipients (inactive ingredients) are in amoxicillin?	amoxicillin excipients list
DailyMed Link:	amoxicillin at DailyMed

See drug prices for amoxicillin

See drug sales revenues for amoxicillin

Recent Clinical Trials for amoxicillin

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Guanxian People's Hospital	NA
Yantai Zhifu Hospital	NA
Agnaldo Rocha de Souza Junior	NA

See all amoxicillin clinical trials

Pharmacology for amoxicillin

Drug Class

Penicillin-class Antibacterial

Medical Subject Heading (MeSH) Categories for amoxicillin

Anti-Bacterial Agents

Anatomical Therapeutic Chemical (ATC) Classes for amoxicillin

J01CA	Penicillins with extended spectrum
J01C	BETA-LACTAM ANTIBACTERIALS, PENICILLINS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for amoxicillin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chartwell Rx	AMOXICILLIN	amoxicillin	FOR SUSPENSION;ORAL	062059-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Cipla	AMOXICILLIN AND CLAVULANATE POTASSIUM	amoxicillin; clavulanate potassium	FOR SUSPENSION;ORAL	065420-001	Dec 2, 2013	AB	RX	No	No
Teva	AMOXICILLIN	amoxicillin	CAPSULE;ORAL	063030-001	Feb 28, 1989		DISCN	No	No
Hikma	AMOXICILLIN	amoxicillin	TABLET, CHEWABLE;ORAL	205274-001	Jun 25, 2020		DISCN	No	No
Sandoz	AMOXICILLIN	amoxicillin	FOR SUSPENSION;ORAL	065387-002	Mar 26, 2007	AB	RX	No	No

Expired US Patents for amoxicillin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pragma	MOXATAG	amoxicillin	TABLET, EXTENDED RELEASE;ORAL	050813-001	Jan 23, 2008	6,544,555
Pragma	MOXATAG	amoxicillin	TABLET, EXTENDED RELEASE;ORAL	050813-001	Jan 23, 2008	6,669,948
Pragma	MOXATAG	amoxicillin	TABLET, EXTENDED RELEASE;ORAL	050813-001	Jan 23, 2008	6,723,341

International Patents for amoxicillin

Country	Patent Number	Title	Estimated Expiration
Australia	2006351475	Modified release amoxicillin products
World Intellectual Property Organization (WIPO)	2008069806
World Intellectual Property Organization (WIPO)	2007067770
China	101563466	Modified release amoxicillin products
Australia	2006321782	Pharmaceutical compositions and methods for improved bacterial eradication

Market Dynamics and Financial Trajectory of Amoxicillin

Last updated: March 14, 2026

What Are the Key Drivers of Amoxicillin Market Growth?

Amoxicillin, a widely prescribed antibiotic in the penicillin class, has maintained a significant position in the global pharmaceutical market. Its growth is primarily driven by the increasing prevalence of infections treatable by beta-lactam antibiotics, including respiratory tract infections, urinary tract infections, and skin infections. The rise in antimicrobial resistance (AMR) among pathogens presents both an obstacle and an opportunity, prompting increased use of amoxicillin combined with beta-lactamase inhibitors like clavulanic acid.

The global amoxicillin market size was valued around $1.2 billion in 2022, with projections reaching approximately $1.6 billion by 2030, growing at a compound annual growth rate (CAGR) of about 4.1% (ResearchAndMarkets, 2022). The increasing burden of infectious diseases in emerging economies and expanding healthcare infrastructure contribute to this growth.

What Are the Market Segments Influencing Sales?

The market can be segmented by formulation, application, and geography:

• Formulation: Capsules, tablets, oral suspensions, and injections.
• Application: Respiratory infections (pneumonia, sinusitis), urinary tract infections, skin and soft tissue infections.
• Geography: North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.

Oral formulations dominate, constituting approximately 80% of sales, driven by outpatient prescription patterns. The Asia-Pacific region accounts for the largest share of the market, led by China and India, due to high infection rates, large populations, and expanding healthcare access.

What Are the Regulatory and Patent Challenges?

While amoxicillin itself has long been off patent, formulations and combination variants are protected by patents. The expiration of patents for key formulations occurred between 2014 and 2018, leading to increased generic competition and pricing pressures.

In 2021, the U.S. Food and Drug Administration (FDA) approved generic versions of amoxicillin tablets and suspensions, expanding market accessibility and reducing prices. Regulatory agencies in Europe and Asia follow similar patent expirations, with generic manufacturers dominating sales.

How Does Antimicrobial Resistance Impact Market Dynamics?

AMR influences prescribing practices, leading to increased usage of combination antibiotics like amoxicillin-clavulanate. The World Health Organization (WHO) reports rising resistance among Streptococcus pneumoniae and Escherichia coli strains, which may reduce amoxicillin’s effectiveness over time.

This situation compels pharmaceutical companies to innovate through formulations and combinations that can overcome resistance mechanisms, fostering new R&D investments and potential novel products.

What Are Financial Trends and Future Projections?

The rising global infection rates, accessible generics, and expanding healthcare coverage support steady revenue streams. Major pharmaceutical firms report consistent sales growth; for example, GlaxoSmithKline, a leading manufacturer, reported amoxicillin sales exceeding $500 million in 2022, with forecasted growth in lower- and middle-income countries.

Pricing varies significantly across regions: $0.50–$1.00 per tablet in North America and Europe versus $0.05–$0.10 in India and China. The proliferation of low-cost generics is expected to continue pressure on branded prices.

Innovation efforts focus on combination therapies that tackle resistance, with some pipelines exploring extended-release formulations and new delivery methods.

How Does Market Competition Shape Financial Outcomes?

The market features dozens of generic manufacturers, including Teva, Sandoz, and Mylan, contributing to fierce price competition. Patent expirations in the last decade led to a wave of price reductions; for example, the median retail price for amoxicillin capsules decreased by over 35% in the U.S. between 2015 and 2021.

Brand-name manufacturers focus on value-added formulations and brand loyalty, but their market share remains limited compared to generics. Volume-driven sales are crucial for profit margins amid shrinking prices.

What Are the Risks and Opportunities Ahead?

Risks:

• Rising antimicrobial resistance could diminish amoxicillin’s efficacy, leading to decreased prescribing.
• Regulatory changes in relation to antibiotic stewardship programs may restrict use.
• Price competition from generics constrains profit margins.

Opportunities:

• Development of novel combination drugs targeting resistant bacteria.
• Expansion in emerging markets via increasing healthcare infrastructure.
• Strategic partnerships for innovation and market access.

Key Takeaways

• The global amoxicillin market is valued at approximately $1.2 billion (2022) with projections reaching $1.6 billion by 2030.
• Growth drivers include rising infection rates, healthcare expansion in emerging markets, and availability of generics.
• Patent expirations have increased generic competition, pressuring prices but enhancing accessibility.
• Antimicrobial resistance influences prescribing trends and creates opportunities for new formulations.
• Price sensitivity remains high, particularly in low- and middle-income countries, affecting revenue stability.

FAQs

How does antimicrobial resistance influence future amoxicillin sales?

Rising resistance among common pathogens may reduce amoxicillin’s effectiveness, leading to decreased usage and shrinking market size unless new formulations or combinations are developed.

Are there new formulations or combinations in development for amoxicillin?

Yes. Research focuses on extended-release formulations, combination therapies with agents overcoming resistance, and novel delivery systems to enhance efficacy and compliance.

What regions pose the highest growth potential?

Emerging markets in Asia-Pacific and Latin America are expected to show significant growth, driven by increasing infection burden, expanding healthcare systems, and the availability of lower-cost generics.

How do patent expirations impact profitability for manufacturers?

Patent expirations enable generic entry, which significantly lowers prices and profit margins. Leading manufacturers counter this effect through innovation, brand positioning, and expanding into high-growth markets.

What are the regulatory trends affecting amoxicillin?

Regulatory agencies support antimicrobial stewardship, which may restrict certain uses. Approvals for new formulations and combination drugs require rigorous clinical data and compliance with antimicrobial resistance policies.

---

References

[1] ResearchAndMarkets. (2022). Global Amoxicillin Market Report. * Retrieved from https://www.researchandmarkets.com

[2] World Health Organization. (2021). Global antimicrobial resistance surveillance system. * Retrieved from https://www.who.int

[3] U.S. Food and Drug Administration. (2021). Approved drugs database. * Retrieved from https://www.fda.gov